Mibefradil and Flunarizine, Two T-Type Calcium Channel Inhibitors, Protect Mice against Lipopolysaccharide-Induced Acute Lung Injury.
MouseEndotoxin/LPSBALB/cMaleIntraperitonealMibefradil 20 and 40 mg/kg; flunarizine 30 mg/kg30 minutes before or 30 minutes after LPS exposure
Model: Lipopolysaccharide-induced acute lung injury, aerosolised LPS 0.5 mg/mL (E. coli 055:B5) for 30 minutes in a chamber
Both mibefradil and flunarizine reduced BALF cell influx, total protein, TNF-alpha and IL-6, Evans blue extravasation, myeloperoxidase activity and histological injury, with mibefradil also suppressing NF-kB activation. Post-treatment was effective but less so than pre-treatment for flunarizine.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.